255 related articles for article (PubMed ID: 18382996)
41. Fetal cardiac defects and increased nuchal translucency thickness: a prospective study.
McAuliffe FM; Hornberger LK; Winsor S; Chitayat D; Chong K; Johnson JA
Am J Obstet Gynecol; 2004 Oct; 191(4):1486-90. PubMed ID: 15507988
[TBL] [Abstract][Full Text] [Related]
42. Cerebro-fronto-facial syndrome (Dandy-Walker Variant and frontofacial dysmorphisms): report of the first case identified by increased nuchal translucency beyond 13(+6) weeks.
Tonni G; Azzoni D; Ambrosetti F; de Felice C; Ventura A
Congenit Anom (Kyoto); 2007 Jun; 47(2):68-71. PubMed ID: 17504390
[TBL] [Abstract][Full Text] [Related]
43. Risk of selected structural abnormalities in infants after increased nuchal translucency measurement.
Baer RJ; Norton ME; Shaw GM; Flessel MC; Goldman S; Currier RJ; Jelliffe-Pawlowski LL
Am J Obstet Gynecol; 2014 Dec; 211(6):675.e1-19. PubMed ID: 24949541
[TBL] [Abstract][Full Text] [Related]
44. Nuchal translucency thickness in euploid fetuses: is two millimeters too risky?
Fink M; Sheiner E; Sheizaf B; Hershkovitz R; Bashiri A; Mazor M; Wiznitzer A
Am J Perinatol; 2009 Apr; 26(4):303-7. PubMed ID: 19031359
[TBL] [Abstract][Full Text] [Related]
45. Nuchal translucency and cardiac abnormalities in euploid singleton pregnancies.
Shamshirsaz AA; Salmanian B; Ravangard SF; Shamshirsaz AA; Javadian P; Borgida A; Turner G; Feldman D; Spiel M; Benn P; Campbell WA
J Matern Fetal Neonatal Med; 2014 Mar; 27(5):495-9. PubMed ID: 23806115
[TBL] [Abstract][Full Text] [Related]
46. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Valencia C; Maiz N; Nicolaides KH
Hum Reprod; 2008 Sep; 23(9):1968-75. PubMed ID: 18544579
[TBL] [Abstract][Full Text] [Related]
47. Fetal echocardiography in trisomy 18.
Moyano D; Huggon IC; Allan LD
Arch Dis Child Fetal Neonatal Ed; 2005 Nov; 90(6):F520-2. PubMed ID: 15914547
[TBL] [Abstract][Full Text] [Related]
48. Prenatal detection of structural cardiac defects and presence of associated anomalies: a retrospective observational study of 1262 fetal echocardiograms.
Mone F; Walsh C; Mulcahy C; McMahon CJ; Farrell S; MacTiernan A; Segurado R; Mahony R; Higgins S; Carroll S; McParland P; McAuliffe FM
Prenat Diagn; 2015 Jun; 35(6):577-82. PubMed ID: 25663276
[TBL] [Abstract][Full Text] [Related]
49. [Screening performance of first trimester nuchal translucency, ductus venosus blood flow and tricuspid regurgitation for cardiac defects].
Geipel A; Gembruch U
Z Geburtshilfe Neonatol; 2012 Aug; 216(4):157-61. PubMed ID: 22926815
[TBL] [Abstract][Full Text] [Related]
50. The performance of an intermediate 16th-week ultrasound scan for the follow-up of euploid fetuses with increased nuchal translucency.
Le Lous M; Bouhanna P; Colmant C; Rozenberg P; Quibel T
Prenat Diagn; 2016 Feb; 36(2):148-53. PubMed ID: 26661276
[TBL] [Abstract][Full Text] [Related]
51. Submicroscopic chromosomal abnormalities in fetuses with increased nuchal translucency and normal karyotype.
Yang X; Li R; Fu F; Zhang Y; Li D; Liao C
J Matern Fetal Neonatal Med; 2017 Jan; 30(2):194-198. PubMed ID: 26998667
[TBL] [Abstract][Full Text] [Related]
52. How important is a cardiac echogenic focus in a routine fetal examination?
Carriço A; Matias A; Areias JC
Rev Port Cardiol; 2004 Mar; 23(3):459-61. PubMed ID: 15185567
[TBL] [Abstract][Full Text] [Related]
53. Pregnancy outcome of euploid fetuses with increased nuchal translucency: how bad is the news?
Maymon R; Weinraub Z; Herman A
J Perinat Med; 2005; 33(3):191-8. PubMed ID: 15914340
[TBL] [Abstract][Full Text] [Related]
54. First-trimester ductus venosus screening for cardiac defects: a meta-analysis.
Papatheodorou SI; Evangelou E; Makrydimas G; Ioannidis JP
BJOG; 2011 Nov; 118(12):1438-45. PubMed ID: 21668765
[TBL] [Abstract][Full Text] [Related]
55. Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?
Bardi F; Bosschieter P; Verheij J; Go A; Haak M; Bekker M; Sikkel E; Coumans A; Pajkrt E; Bilardo C
Prenat Diagn; 2020 Jan; 40(2):197-205. PubMed ID: 31697852
[TBL] [Abstract][Full Text] [Related]
56. Pregnancy outcome for fetuses with increased nuchal translucency but normal karyotype.
Lithner CU; Kublickas M; Ek S
J Med Screen; 2016 Mar; 23(1):1-6. PubMed ID: 26195563
[TBL] [Abstract][Full Text] [Related]
57. Screening for triploidy by the risk algorithms for trisomies 21, 18 and 13 at 11 weeks to 13 weeks and 6 days of gestation.
Kagan KO; Anderson JM; Anwandter G; Neksasova K; Nicolaides KH
Prenat Diagn; 2008 Dec; 28(13):1209-13. PubMed ID: 19039823
[TBL] [Abstract][Full Text] [Related]
58. Nuchal translucency and the risk of congenital heart disease.
Simpson LL; Malone FD; Bianchi DW; Ball RH; Nyberg DA; Comstock CH; Saade G; Eddleman K; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; D'Alton ME
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):376-83. PubMed ID: 17267839
[TBL] [Abstract][Full Text] [Related]
59. Measurement of nuchal translucency for prenatal screening of congenital heart defects: a population-based evaluation.
Jouannic JM; Thieulin AC; Bonnet D; Houyel L; Lelong N; Goffinet F; Khoshnood B
Prenat Diagn; 2011 Dec; 31(13):1264-9. PubMed ID: 22028040
[TBL] [Abstract][Full Text] [Related]
60. Prenatal detection of congenital heart disease.
Friedberg MK; Silverman NH; Moon-Grady AJ; Tong E; Nourse J; Sorenson B; Lee J; Hornberger LK
J Pediatr; 2009 Jul; 155(1):26-31, 31.e1. PubMed ID: 19394031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
